Market closed
Actinium Pharmaceuticals/$ATNM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Actinium Pharmaceuticals
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Ticker
$ATNM
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
49
Website
ATNM Metrics
BasicAdvanced
$57M
Market cap
-
P/E ratio
-$1.52
EPS
0.20
Beta
-
Dividend rate
Price and volume
Market cap
$57M
Beta
0.2
52-week high
$10.24
52-week low
$1.33
Average daily volume
251K
Financial strength
Current ratio
8.95
Quick ratio
8.844
Long term debt to equity
2.961
Total debt to equity
4.218
Management effectiveness
Return on assets (TTM)
-30.91%
Return on equity (TTM)
-87.96%
Valuation
Price to revenue (TTM)
635.417
Price to book
1.28
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-1.514
Growth
Revenue change (TTM)
80.00%
Earnings per share change (TTM)
-16.11%
3-year revenue growth (CAGR)
-54.99%
3-year earnings per share growth (CAGR)
6.03%
What the Analysts think about ATNM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Actinium Pharmaceuticals stock.
ATNM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATNM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATNM News
AllArticlesVideos
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
Accesswire·5 days ago
Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
Accesswire·6 days ago
Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Actinium Pharmaceuticals stock?
Actinium Pharmaceuticals (ATNM) has a market cap of $57M as of November 08, 2024.
What is the P/E ratio for Actinium Pharmaceuticals stock?
The price to earnings (P/E) ratio for Actinium Pharmaceuticals (ATNM) stock is 0 as of November 08, 2024.
Does Actinium Pharmaceuticals stock pay dividends?
No, Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Actinium Pharmaceuticals dividend payment date?
Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Actinium Pharmaceuticals?
Actinium Pharmaceuticals (ATNM) has a beta rating of 0.2. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.